Stock Forecast Chart
Stock Price Prediction Summary
Forecast Score Based on 2 Weeks
Based on our forecast, the price of ELVN will decline by -3.04% over the next 2 Weeks and hit $52.78 by Monday, September 28, 2026. In that time frame, ELVN's share price is expected to range between $50.99 and $54.45.
BearishAverageBullish| Date | Predicted Lower | Predicted | Predicted Upper |
|---|---|---|---|
| Sep 28, 2026 | 50.99 | 52.78 | 54.45 |
| Sep 25, 2026 | 51.18 | 52.82 | 54.34 |
| Sep 24, 2026 | 51.30 | 52.83 | 54.37 |
| Sep 23, 2026 | 51.37 | 53.05 | 54.48 |
| Sep 22, 2026 | 52.45 | 53.97 | 55.35 |
| Sep 21, 2026 | 52.15 | 53.56 | 54.81 |
| Sep 18, 2026 | 52.28 | 53.61 | 54.99 |
| Sep 17, 2026 | 52.33 | 53.62 | 54.90 |
| Sep 16, 2026 | 52.55 | 53.84 | 55.05 |
| Sep 15, 2026 | 53.45 | 54.76 | 55.98 |
ELVN shares fell -1.69% in Tuesday, September 15, 2026's trading session, dropping from a previous close of $54.43 to move at $53.51. The stock demonstrated notable intraday movement (see ELVN's key stats for a full breakdown), fluctuating between $52.98 and $54.50, a +2.87% trading range. While recent weeks have seen some volatility, ELVN has managed to secure a -7.57% drop over the past 2 weeks. The downward price movement was accompanied by decreased trading volume, with approximately 806.16K shares changing hands, 189.65K fewer than the previous session. This amounted to $43.14M in total market activity.
Will ELVN Continue Its Upward Trend?
According to analyst ratings and projections for ELVN, Enliven Therapeutics, Inc. shares are anticipated to increase by +1.72%, potentially reaching $54.45 per share by September 28, 2026. Short-term technical indicators currently suggest a neutral sentiment for ELVN. For deeper insights, view our sentiment analysis on AAPL covering social and institutional perspectives. However, the stock has recorded 15 positive trading days within the past 30 sessions. Based on the ELVN stock forecast, now is a good time to buy ELVN stock because its current trading price is +1.39% above our predicted value, hinting at a possible undervaluation. For deeper insights, view our sentiment analysis on ELVN covering social and institutional perspectives.
ELVN Technical Momentum: Overbought, Oversold, or Neutral?
An analysis of Relative Strength Index (RSI) indicators provides insight into ELVN's momentum. Short-term RSIs (9, 14, and 20-day figures ranging from 22.84% to 41.43%) suggest weak bearish momentum with possible fluctuation. The 50-day RSI, at 53.06%, suggests a neutral medium-term outlook. Additionally, the 100-day RSI, at 55.52%, maintains a neutral outlook for the long term. Insights into ELVN's shareholder base show how institutional investors are positioning themselves during these momentum shifts
Enliven Therapeutics Short-Term Forecasts
ELVN Forecast For Next 5 Days
Our algorithm anticipates Enliven Therapeutics (ELVN) stock could hit $56.04 by Sep 22, 2026. This represents a +4.73% rise from today's price, following a +8.07% change over the past five days.
ELVN Forecast For Next 30 Days
Based on analysis of market trends, the outlook for Enliven Therapeutics, Inc. (ELVN) stock over the next 30 days is largely positive. Price forecasts suggest an average target of $56.89, which would mean a +6.32% increase from the current price of $53.51. Projections for this period range from a high of $60.91 to a low of $53.35.
ELVN Forecast For Next 90 Days
Our proprietary market analysis suggests predictions for Enliven Therapeutics's price over the next three months point to a rise. ELVN stock is expected to peak at $59.90 on Dec 10, 2026 after potentially dipping to $49.23 on Sep 17, 2026. On average, ELVN is likely to trade around $54.52 in the coming 90 days.
Enliven Therapeutics Stock Forecast 2025
Based on our predictive models, Enliven Therapeutics (ELVN) is expected to trade between $49.23 and $61.03 throughout 2026. This would result in an average price of $54.89, potentially offering investors a +2.58% return from current levels.
Enliven Therapeutics, Inc. Monthly Forecast 2026–2027
September 2026
According to our latest forecast models, Enliven Therapeutics, Inc. (ELVN) is positioned to show a strong performance in September 2026. The price is predicted to move between $49.23 and $56.17, settling at an average of $52.97. This could translate to a -1.01% loss.
October 2026
Based on current market signals, Enliven Therapeutics, Inc. is projected to trend october 2026. We forecast a trading range from $49.83 to $57.42, with a likely average price of $53.59. Investors could expect a potential return of +0.15%.
November 2026
Our predictive algorithms indicate Enliven Therapeutics, Inc. stock may see a shift in November 2026. The expected range spans $50.47–$59.82, with an average target of $55.57. This represents a positive outlook and a possible gain of +3.85%.
December 2026
Analyzing established trends, Enliven Therapeutics, Inc. looks set to move in December 2026. Projections place the stock between $52.15 and $61.03, averaging around $56.51. This suggests a +5.61% gain from current levels.
January 2027
Market indicators suggest Enliven Therapeutics, Inc. could experience notable changes during January 2027. Prices could fluctuate within $54.00 to $61.52, with a midpoint forecast of $57.89. The stock might deliver a +8.19% gain.
February 2027
Forecasting for February 2027, models estimate that Enliven Therapeutics, Inc. may undergo key fluctuations. If trends hold, the stock might trade between $53.01 and $62.07, averaging $57.21. This signals a positive trajectory with potential returns around +6.91%.
March 2027
According to our latest forecast models, Enliven Therapeutics, Inc. (ELVN) is positioned to show a strong performance in March 2027. The price is predicted to move between $53.10 and $61.29, settling at an average of $57.09. This could translate to a +6.69% gain.
April 2027
Based on current market signals, Enliven Therapeutics, Inc. is projected to trend april 2027. We forecast a trading range from $54.20 to $63.51, with a likely average price of $59.26. Investors could expect a potential return of +10.75%.
May 2027
Our predictive algorithms indicate Enliven Therapeutics, Inc. stock may see a shift in May 2027. The expected range spans $55.96–$64.15, with an average target of $60.04. This represents a positive outlook and a possible gain of +12.20%.
June 2027
Analyzing established trends, Enliven Therapeutics, Inc. looks set to move in June 2027. Projections place the stock between $57.51 and $65.25, averaging around $61.37. This suggests a +14.69% gain from current levels.
July 2027
Market indicators suggest Enliven Therapeutics, Inc. could experience notable changes during July 2027. Prices could fluctuate within $56.18 to $65.42, with a midpoint forecast of $60.47. The stock might deliver a +13.01% gain.
August 2027
Forecasting for August 2027, models estimate that Enliven Therapeutics, Inc. may undergo key fluctuations. If trends hold, the stock might trade between $57.00 and $64.37, averaging $60.71. This signals a positive trajectory with potential returns around +13.46%.
September 2027
According to our latest forecast models, Enliven Therapeutics, Inc. (ELVN) is positioned to show a strong performance in September 2027. The price is predicted to move between $58.03 and $66.66, settling at an average of $62.78. This could translate to a +17.32% gain.
ELVN's history of dividends and stock splits also plays a role in long-term investor confidence.